Physician
Oncology
Dr. Paulo M. Hoff, MD
|
|
Give Review
Paulo Hoff is an expert in the field of Oncology. Paulo Hoff has written publications. He has 61 publications published with PubMed. The lastest paper is: 'Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroe...'
Publications
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroe...
- Association between KRAS mutation and lung metastasis in advanced colorectal cancer.
- Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized T...
- Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity.
- Squamous-cell carcinoma of the anal canal: Room for improvement with targeted therapy.
- Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
- Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients.
- Immune-mediated pancytopenia induced by oxaliplatin: a case report.
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
- Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with...
- Symptomatic hypoglycemia related to inappropriately high igf-ii serum levels in a patient with desmoplastic small round cell tumor.
- Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
- Peritonectomy for peritoneal carcinomatosis: long-term outcomes from a single Brazilian institution.
- Perioperative treatment of gastrointestinal stromal tumors.
- Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
- Potential regional differences for the tolerability profiles of fluoropyrimidines.
- Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interfe...
- Adjuvant chemotherapy for stage II colon cancer.
- Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness.
- Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-...
- EGFR-targeted therapies in colorectal cancer.
- Molecular targeted therapy for neuroendocrine tumors.
- Targeted therapy trials: approval strategies, target validation, or helping patients?
- Novel agents and targets for the therapy of advanced colon cancer.
- Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
- Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
- Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
- Selection of patients for resection of hepatic colorectal metastases: expert consensus statement by Charnsangavej et al.
- Bevacizumab in older patients and patients with poorer performance status.
- Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
- Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
- Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision...
- Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
- Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.
- Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
- Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management.
- Is there a role for routine p53 testing in colorectal cancer?
- Chemotherapy of Metastatic Colorectal Cancer.
- Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal met...
- Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
- Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
- Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
- Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
- Progress in the development of novel treatments for colorectal cancer.
- Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
- Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer.
- Molecular-targeted agents in pancreatic cancer.
- A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon...
- The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas.
- Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer.
- Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
- UFT and oral leucovorin as radiation sensitizers in rectal and other gastrointestinal malignancies.
- Acinar cell carcinoma of the pancreas.
- Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.
- Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
- Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
- Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
- Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.
Schools
University of Brazil Foundation Faculty of Health Science
Jackson Memorial Hospital
MD Anderson Cancer Center
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
|
Dr. Anita Sabichi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Lehane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ajjai S. Alva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sattva S. Neelapu, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joseph A. Ludwig IV, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vinod K. Bhuchar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anthony P. Conley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick Hwu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa G. Hayes, MD |
|
|
Dr. Inhye Ahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mindy Hsiong, MD
This Doctor is OpenDoctor Recommended.
|